Compare Globus Medical Inc. Class A Common Stock (GMED) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Wells Fargo & Co — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.85 (market cap $10.25B), while Wells Fargo & Co trades at $81.54 (market cap $242.83B). The key difference: Wells Fargo & Co is far larger — about 23.7× Globus Medical Inc. Class A Common Stock's market cap, and Wells Fargo & Co pays a 2.47% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Wells Fargo & Co for 88 Days on average.
| GMED | WFC | |
|---|---|---|
Market Cap | $10.25B | $242.83B |
Volume | 1,059,528 | 21,447,763 |
Sector | Health | Financials |
52-Week High | $96.82 | $96.40 |
52-Week Low | $58.33 | $73.42 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $9.76B | $425.14B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Wells Fargo (WFC) trades at $80.74, down 3.07% on the day, amid mixed technical signals with a bullish overall signal but bearish moving averages. The company shows solid fundamentals with a P/E of 11.76, net income margin of 25.97%, and recent earnings beats in Q2 and Q3 2026. Positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and a renewed mortgage servicing agreement with Intercontinental Exchange (Business Wire, 2026-09-29).
The outlook is supported by analyst consensus with a $98 price target and a balanced buy/hold rating split, though risks include volatile cash flows and regulatory changes from Fed stress test overhauls (Reuters, 2026-09-30). Upside potential hinges on continued earnings growth and NII expansion from rate hikes, while downside risks involve execution challenges and macroeconomic pressures on banking stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
